The financing will support the commercial rollout of synthetic affinity reagents and team expansion.
"Securing funding for a novel reagents company in today's investment landscape demonstrates clear confidence in MIP Discovery's technology and renewed commercial strategy. Our proprietary modeling approach to developing synthetic antibody alternatives has already been successful for diagnostic applications, and we have already seen very encouraging traction for our expertise in the cell and gene therapy space."
The funding round was backed by Mercia Ventures, Northstar Ventures, and the North East Venture Fund.
"The support from our investors has allowed us to grow the business to the point where we now work with over 100 customers internationally including large pharma and biotech companies. This latest investment will further enhance our technology and underpin our ability to continue our rapid growth."
The funding extension was backed by new investor We Venture Capital alongside returning backers Nina Capital, Apex Ventures, and Cambridge Enterprise to prepare the firm for Series A.
"Zetta Genomics is already making a difference to patients as XetaBase empowers clinicians to make faster and more accurate diagnoses at scale. With this extension to our second seed funding round now finalised, we are scaling and innovating our technologies, and enhancing customer focus."
The pre seed round was led by Episode 1 Ventures and will support infrastructure development and team expansion.
"We are really excited, this investment will help Sable Bio redefine drug safety assessment and change the ways actionable biomedical insights are generated. Working with with leading investors Episode 1 and Seedcamp is enabling us to build an exceptional team and a platform to accelerate safer drug development for patients in need"
The Edinburgh biotech uses the capital to scale its 3D bioprinted tumour models across the UK, Europe, and the US.
"Our vision is to be at the forefront of cancer drug testing and provide personalised medicine testing to every individual suffering from cancer to improve their treatment and chance of survival. Working with global partners, leading pharma companies, surgeons, pathologists, and clinicians, Carcinotech aims to accelerate oncology drug development significantly."
